TREATMENT OF OCULAR DISEASE
Disclosed are methods for treating eye diseases or conditions characterized by vascular instability, vascular leakage and neovacularization such as diabetic macular edema, age-related macular edema, choroidal neovascularization, diabetic retinopathy, trauma, ocular ischemia, retinal angiomatous proliferation, macular telangiectasia and uveitis.
1 - 20 . (canceled)
21 . A pharmaceutical composition comprising a therapeutically-effective amount of a multi-specific antibody, wherein the multi-specific antibody binds to a human protein tyrosine phosphatase beta-extracellular domain (HPTPβ-ECD) in a subject, and wherein the therapeutically-effective amount of the multi-specific antibody is from about 0.01 mg/kg to about 500 mg/kg by weight of the subject.
22 . The pharmaceutical composition of claim 21 , wherein the multispecific antibody binds to an FN3 repeat in the HPTPβ-ECD.
23 . The pharmaceutical composition of claim 21 , wherein the multispecific antibody binds to a first FN3 repeat in the HPTPβ-ECD.
24 . The pharmaceutical composition of claim 21 , wherein the multispecific antibody inhibits HPTPβ.
25 . The pharmaceutical composition of claim 21 , wherein the multispecific antibody binds to SEQ ID NO.: 4.
25 . The pharmaceutical composition of claim 21 , wherein the pharmaceutical composition is a solution, and the solution has a pH of from about 7 to about 7.5.
26 . The pharmaceutical composition of claim 21 , wherein the multi-specific antibody is a bispecific antibody.
27 . The pharmaceutical composition of claim 21 , wherein the therapeutically-effective amount of the multi-specific antibody is from about 0.1 mg/kg to about 50 mg/kg.
28 . The pharmaceutical composition of claim 21 , further comprising a carrier.
29 . A method for treating an ocular condition in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition, wherein the pharmaceutical composition comprises a therapeutically-effective amount of a multi-specific antibody, wherein the multi-specific antibody binds to a human protein tyrosine phosphatase beta-extracellular domain (HPTPβ-ECD) in a subject, and wherein the therapeutically-effective amount of the multi-specific antibody is from about 0.01 mg/kg to about 500 mg/kg by weight of the subject.
30 . The method of claim 29 , wherein the multispecific antibody binds to an FN3 repeat in the HPTPβ-ECD.
31 . The method of claim 29 , wherein the multispecific antibody binds to a first FN3 repeat in the HPTPβ-ECD.
32 . The method of claim 29 , wherein the multispecific antibody inhibits HPTPβ.
33 . The method of claim 29 , wherein the multispecific antibody binds to SEQ ID NO.: 4.
34 . The method of claim 29 , wherein the pharmaceutical composition is a solution, and the solution has a pH of from about 7 to about 7.5.
35 . The method of claim 29 , wherein the multi-specific antibody is a bispecific antibody.
36 . The method of claim 29 , wherein the therapeutically-effective amount of the multi-specific antibody is from about 0.1 mg/kg to about 50 mg/kg.
37 . The method of claim 29 , wherein the pharmaceutical composition is administered by intraocular injection.
38 . The method of claim 29 , wherein the pharmaceutical composition is administered by subcutaneous injection.
39 . The method of claim 29 , wherein the pharmaceutical composition is administered by intravenous injection.
40 . The method of claim 29 , wherein the subject is human.
41 . The method of claim 29 , wherein the pharmaceutical composition further comprises a carrier.